


**2'OMe-CTP**

2'-O-Methylcytidine-5'-triphosphate, Sodium salt

Cat. No.	Amount
NU-1211S	50 µl (100 mM)
NU-1211L	5 x 50 µl (100 mM)



Structural formula of 2'OMe-CTP

For general laboratory use.**Shipping:** shipped on gel packs**Storage Conditions:** store at -20 °C

Short term exposure (up to 1 week cumulative) to ambient temperature possible.

Shelf Life: 12 months after date of delivery**Molecular Formula:** C₁₀H₁₈N₃O₁₄P₃ (free acid)**Molecular Weight:** 497.18 g/mol (free acid)**Exact Mass:** 497.00 g/mol (free acid)**Purity:** ≥ 95 % (HPLC)**Form:** solution in water**Color:** colorless to slightly yellow**Concentration:** 100 mM - 110 mM**pH:** 7.5 ±0.5**Spectroscopic Properties:** λ_{max} 271 nm, ε 9.1 L mmol⁻¹ cm⁻¹ (Tris-HCl pH 7.5)**Selected References:**Lauridsen *et al.* (2012) Enzymatic recognition of 2'-modified ribonucleoside 5'-triphosphates: towards the evolution of versatile aptamers. *Chembiochem.* **13** (1):19.Xiao *et al.* (2012) Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection. *ACS Nano* **6** (1):696.Keefe *et al.* (2008) SELEX with modified nucleotides. *Curr. Opin. Chem. Biol.* **12** (4):448.Burmeister *et al.* (2006) 2'-Deoxy purine, 2'-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics. *Oligonucleotides* **16** (4):337.Dutartre *et al.* (2006) General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide Analogues. *Antimicrob. Agents Chemother.* **50** (12):4161.Burmeister *et al.* (2005) Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. *Chem. Biol.* **12** (1):25.